Register for SOSV Deep Tech Live – Dr. Rick Gottscho on Plasma & Semiconductors

Asta Bio

Reimagining Cancer Treatment with Targeted Radiotherapy

Company details

Our technology combines 211-Astatine, the most druggable alpha-emitting radioisotope, with multivalent single-domain antibodies to deliver potent alpha radiation that breaks DNA strands and kills the tumor cells while leaving normal cells unaffected.

18 million cancer patients are diagnosed each year worldwide, with the majority suffering from advanced metastatic disease. About 90% of patients living with metastatic cancer will die of it.

Asta Bio Quote Image
Ahmad-Reza Saadat, Co-Founder and CEO
Radiation is one of the most effective tools we have to treat cancer. The challenge is harnessing that power to target tumors more precisely without harming the patient and to make it more widely available. That’s what we're doing.

Team

Ahmad Reza Saadat

CEO

Rebekah O’Donnell

CSO

Get In Touch with Asta Bio

Please tell us a little bit about yourself and why you'd like to get connected. Asta Bio + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.